Stock TNYA TENAYA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Tenaya Therapeutics, Inc.

Equities

TNYA

US87990A1060

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
4.21 USD +0.72% Intraday chart for Tenaya Therapeutics, Inc. -7.27% +29.94%
May. 16 Canaccord Genuity Adjusts Tenaya Therapeutics Price Target to $16 From $18, Maintains Buy Rating MT
May. 14 Tenaya Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Business Summary

Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. The Company’s advanced product candidates include TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed to treat the underlying cause of MYBPC3 associated HCM by delivering a working MYBPC3 gene to specific cells of the heart via a single infusion. TN-401 is the Company’s adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene. TN-301 is a small molecule for heart failure with preserved ejection fraction.

Number of employees: 140

Managers

Managers TitleAgeSince
Faraz Ali CEO
 Chief Executive Officer 51 18-05-31
Leone Patterson DFI
 Director of Finance/CFO 61 21-05-31
Kee-Hong Kim CTO
 Chief Tech/Sci/R&D Officer - 18-09-30
Whittemore Tingley CTO
 Chief Tech/Sci/R&D Officer 56 18-11-30
Matthew Jay Pollman CTO
 Chief Tech/Sci/R&D Officer - -
Timothy Hoey CTO
 Chief Tech/Sci/R&D Officer 65 17-07-31
Michelle Corral IRC
 Investor Relations Contact - -
Sunita Sethi LAW
 General Counsel - -
Jennifer Drimmer LAW
 General Counsel - 22-01-09
Joanna Auch HRO
 Human Resources Officer - 21-12-21

Members of the board

Members of the board TitleAgeSince
Robert Williams BRD
 Director/Board Member 75 16-09-30
David Goeddel CHM
 Chairman 72 16-07-31
Jeffrey Walsh BRD
 Director/Board Member 58 20-02-29
Jin Long Chen BRD
 Director/Board Member 61 16-09-30
Deepak Srivastava FOU
 Founder 57 16-09-30
Faraz Ali CEO
 Chief Executive Officer 51 18-05-31
Karah Parschauer BRD
 Director/Board Member 46 21-12-21
June Lee BRD
 Director/Board Member 58 21-11-18
Catherine Stehman-Breen BRD
 Director/Board Member 61 20-05-31
Amy Burroughs BRD
 Director/Board Member 54 22-12-06

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 78,517,534 77,177,932 ( 98.29 %) 0 98.29 %

Shareholders

NameEquities%Valuation
The Column Group LLC
11.97 %
9,400,290 11.97 % 40 M $
Casdin Capital LLC
8.575 %
6,732,971 8.575 % 28 M $
RA Capital Management LP
7.330 %
5,755,050 7.330 % 24 M $
BlackRock Advisors LLC
5.770 %
4,530,475 5.770 % 19 M $
T. Rowe Price International Ltd.
4.262 %
3,346,522 4.262 % 14 M $
Fidelity Management & Research Co. LLC
3.706 %
2,910,126 3.706 % 12 M $
Vanguard Fiduciary Trust Co.
3.646 %
2,862,916 3.646 % 12 M $
Octagon Capital Advisors LP
3.635 %
2,854,000 3.635 % 12 M $
Integral Health Asset Management LLC
2.866 %
2,250,000 2.866 % 9 M $
Citadel Securities GP LLC
2.862 %
2,247,516 2.862 % 9 M $

Company contact information

Tenaya Therapeutics, Inc.

171 Oyster Point Boulevard 5th floor

94080, South San Francisco

+

http://www.tenayatherapeutics.com
address Tenaya Therapeutics, Inc.(TNYA)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
4.21 USD
Average target price
19.29 USD
Spread / Average Target
+358.09%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
TENAYA THERAPEUTICS, INC. Stock Tenaya Therapeutics, Inc.
+29.94% 331M
MODERNA, INC. Stock Moderna, Inc.
+43.36% 54.63B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.31% 39.92B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.75% 26.86B
CELLTRION, INC. Stock Celltrion, Inc.
-12.56% 26.22B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.45% 18.78B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.12% 12.21B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.04% 12.16B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.04% 11.94B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-11.83% 10.74B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. TNYA Stock
  4. Company Tenaya Therapeutics, Inc.